MAPK3 and melanoma: Activation of ERK1/2 was observed by immunohistochemistry in 54% of primary and 33% of metastastic melanomas, respectively11, MUG-Mel2 presents a high activated (phosphorylated) ERK1/2, significant more activated compared to WM 164, a BRAF mutated cell line.